ZFP36 and neoplasm: The results of drug sensitivity and drug resistance analysis showed that the expression of ZFP36 in tumor tissues of GC patients was associated with resistance to CGP60474 and gefitinib, and sensitivity to camptothecin, SB52334, talazopanib, and TW37.